
The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.
Reducing Protocol Burden to Improve Trial Performance (Sponsored)
Clinical trial teams face a difficult balance: preserve scientific rigor while making protocols feasible for sites and participants. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Metta Anderson, general manager of data analytics and insights at WCG, about how protocol burd…
17:23
Digital Twins: Advancing Clinical Evidence Strategy (Sponsored)
Patient digital twins give life sciences teams a framework for evaluating how an individual patient’s health trajectory could change under different treatments or scenarios. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Nadea Leavitt, a clinical statistician and AI researc…
20:08
The promise of molecular gates and what comes next
Gate Bioscience is betting that a decades-old biological mechanism could pave the way for a new class of medicines. The biotech is developing small molecules that selectively block disease-causing proteins from passing through a cellular channel called Sec61, causing them to be degraded before they…
14:04
How Smarter Healthcare Environments Improve Patient Experience (Sponsored)
Patient experience is shaped by more than clinical care. It begins with transportation, parking and wayfinding, and continues through check-in, the patient room, diagnostics and follow-up. In this sponsored episode of Podnosis, host Irena Luo speaks with Candace LeVaughn, industry principal of heal…
25:43
Use Kidney Genetics to Strengthen Clinical Trial Design (Sponsored)
Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation. In this sponsored episode of The Top Line, Will Hurth speaks with Dr. Ronen Schneider, medical director of renal genetics at Natera, about t…
15:05
When China Fits a Global Clinical Development Strategy (Sponsored)
China can play several roles in a global clinical development program, from supporting a capital-efficient proof-of-concept study to contributing evidence within a multiregional clinical trial. In this sponsored episode of The Top Line, Caidya Chief Operating Officer Mike Clay and Vice President of…
17:35
There's more than one way to build a biotech
As biotech companies continue to navigate a challenging funding environment, Axiom Biosciences is taking an unconventional approach to raising capital and developing new therapies. The company is pursuing a public listing in Hong Kong, with ambitions to eventually list on the Nasdaq. Meanwhile, it…
16:39
When drug development gets personal
For nearly three decades, Jigar Raythatha has helped build biotech companies and bring new medicines to patients. But in 2023, the Third Rock Ventures partner found himself on the other side of drug development when he was diagnosed with a rare form of brain cancer. In a remarkable coincidence, th…
28:19
How AI turns field conversations into actionable insights (Sponsored)
Life science field teams are a major source of customer insight, but growing complexity, limited HCP access and expanding omnichannel demands can make it difficult to turn every interaction into action. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Nick Syndercombe, STEM A…
16:28
GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing
In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the growing role of point-of-care advertising in pharmaceutical marketing. First, we look at GSK's big week, which included FDA approval for Jemperl…
15:25